Inherent genome instability underlies trisomy 21-associated myeloid malignancies

Leukemia. 2024 Mar;38(3):521-529. doi: 10.1038/s41375-024-02151-8. Epub 2024 Jan 20.

Abstract

Constitutional trisomy 21 (T21) is a state of aneuploidy associated with high incidence of childhood acute myeloid leukemia (AML). T21-associated AML is preceded by transient abnormal myelopoiesis (TAM), which is triggered by truncating mutations in GATA1 generating a short GATA1 isoform (GATA1s). T21-associated AML emerges due to secondary mutations in hematopoietic clones bearing GATA1s. Since aneuploidy generally impairs cellular fitness, the paradoxically elevated risk of myeloid malignancy in T21 is not fully understood. We hypothesized that individuals with T21 bear inherent genome instability in hematopoietic lineages that promotes leukemogenic mutations driving the genesis of TAM and AML. We found that individuals with T21 show increased chromosomal copy number variations (CNVs) compared to euploid individuals, suggesting that genome instability could be underlying predisposition to TAM and AML. Acquisition of GATA1s enforces myeloid skewing and maintenance of the hematopoietic progenitor state independently of T21; however, GATA1s in T21 hematopoietic progenitor cells (HPCs) further augments genome instability. Increased dosage of the chromosome 21 (chr21) gene DYRK1A impairs homology-directed DNA repair as a mechanism of elevated mutagenesis. These results posit a model wherein inherent genome instability in T21 drives myeloid malignancy in concert with GATA1s mutations.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aneuploidy
  • Child
  • DNA Copy Number Variations
  • Down Syndrome* / complications
  • GATA1 Transcription Factor / genetics
  • Genomic Instability
  • Humans
  • Leukemia, Myeloid, Acute* / pathology
  • Leukemoid Reaction*
  • Myeloproliferative Disorders* / genetics
  • Trisomy

Substances

  • GATA1 Transcription Factor

Supplementary concepts

  • Myeloproliferative Syndrome, Transient